| scholarly article | Q13442814 |
| P2093 | author name string | Janet Klein | |
| Michael G Wilson | |||
| Michael P Murphy | |||
| Jeffrey H Lawson | |||
| Gary D Hutchins | |||
| Keith L March | |||
| Brian M Rapp | |||
| Michael C Dalsing | |||
| P2860 | cites work | Isolation of putative progenitor endothelial cells for angiogenesis | Q28302884 |
| Augmentation of postnatal neovascularization with autologous bone marrow transplantation | Q30979202 | ||
| Regional measurement of canine skeletal muscle blood flow by positron emission tomography with H2(15)O. | Q31042631 | ||
| Excimer laser assisted angioplasty for critical limb ischemia: results of the LACI Belgium Study | Q33214760 | ||
| A blinded, randomized, placebo-controlled trial of percutaneous laser myocardial revascularization to improve angina symptoms in patients with severe coronary disease | Q33227138 | ||
| Results of a double-blind, placebo-controlled study to assess the safety of intramuscular injection of hepatocyte growth factor plasmid to improve limb perfusion in patients with critical limb ischemia | Q33344368 | ||
| Autologous bone marrow cell transplantation increases leg perfusion and reduces amputations in patients with advanced critical limb ischemia due to peripheral artery disease | Q33462060 | ||
| Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization | Q33870103 | ||
| Predicting which patients will develop chronic critical leg ischemia. | Q33897504 | ||
| The fate of patients with critical leg ischemia | Q33897509 | ||
| Is the placebo powerless? An analysis of clinical trials comparing placebo with no treatment | Q33948133 | ||
| Bypass versus Angioplasty in Severe Ischaemia of the Leg (BASIL) and the (hoped for) dawn of evidence-based treatment for advanced limb ischemia | Q34113239 | ||
| Medical treatment of peripheral arterial disease and claudication | Q34260697 | ||
| Bypass versus angioplasty in severe ischaemia of the leg (BASIL): multicentre, randomised controlled trial | Q34472601 | ||
| A decade of experience with dorsalis pedis artery bypass: analysis of outcome in more than 1000 cases | Q35058464 | ||
| Transplantation of ex vivo expanded endothelial progenitor cells for therapeutic neovascularization | Q35111623 | ||
| Use of autologous bone marrow mononuclear cell implantation therapy as a limb salvage procedure in patients with severe peripheral arterial disease | Q39297003 | ||
| Unblinded pilot study of autologous transplantation of bone marrow mononuclear cells in patients with thromboangiitis obliterans | Q39342745 | ||
| Autologous bone-marrow mononuclear cell implantation for patients with Rutherford grade II-III thromboangiitis obliterans. | Q39346993 | ||
| Natural history of limbs with arterial insufficiency and chronic ulceration treated without revascularization | Q39348816 | ||
| Clinical application of bone marrow implantation in patients with arteriosclerosis obliterans, and the association between efficacy and the number of implanted bone marrow cells | Q39701367 | ||
| Origin of endothelial progenitors in human postnatal bone marrow | Q39737487 | ||
| Comparison of generic and disease-specific questionnaires for the assessment of quality of life in patients with peripheral arterial disease | Q40437967 | ||
| Infrapopliteal angioplasty for critical limb ischemia: relation of TransAtlantic InterSociety Consensus class to outcome in 176 limbs | Q44353178 | ||
| Therapeutic angiogenesis by autologous bone marrow cell implantation for refractory chronic peripheral arterial disease using assessment of neovascularization by 99mTc-tetrofosmin (TF) perfusion scintigraphy | Q45093502 | ||
| Postoperative and late survival outcomes after major amputation: findings from the Department of Veterans Affairs National Surgical Quality Improvement Program | Q45334298 | ||
| Parenteral therapy with lipo-ecraprost, a lipid-based formulation of a PGE1 analog, does not alter six-month outcomes in patients with critical leg ischemia | Q46251338 | ||
| Revascularization and quality of life for patients with limb-threatening ischemia. | Q51069549 | ||
| Percutaneous peripheral atherectomy of femoropopliteal stenoses using a new-generation device: six-month results from a single-center experience. | Q51563085 | ||
| TcPO2 as an accurate predictor of therapy in limb salvage. | Q52305772 | ||
| Surgery as a placebo. | Q53861565 | ||
| Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II) | Q56287926 | ||
| Assessment of quality of life of patients with severe ischemia as a result of infrainguinal arterial occlusive disease | Q68186456 | ||
| Transcutaneous oxygen (TcPO2) estimates probability of healing in the ischemic extremity | Q70994690 | ||
| The costs of managing lower limb-threatening ischaemia | Q71735338 | ||
| Neovascularization induced by autologous bone marrow cell implantation in peripheral arterial disease | Q73004319 | ||
| Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-marrow cells: a pilot study and a randomised controlled trial | Q74811727 | ||
| Two-year outcome with preferential use of infrainguinal angioplasty for critical ischemia | Q82743882 | ||
| P433 | issue | 6 | |
| P921 | main subject | amputation | Q477415 |
| P304 | page(s) | 1565-74.e1 | |
| P577 | publication date | 2011-04-22 | |
| P1433 | published in | Journal of Vascular Surgery | Q15755733 |
| P1476 | title | Autologous bone marrow mononuclear cell therapy is safe and promotes amputation-free survival in patients with critical limb ischemia | |
| P478 | volume | 53 |
| Q37344037 | A phase I study of human cord blood-derived mesenchymal stem cell therapy in patients with peripheral arterial occlusive disease |
| Q40747899 | Analysis of migration rate and chemotaxis of human adipose-derived mesenchymal stem cells in response to LPS and LTA in vitro |
| Q27026719 | Autologous bone marrow cell therapy for peripheral arterial disease |
| Q52689443 | Autologous bone marrow-derived mononuclear cell therapy in Chinese patients with critical limb ischemia due to thromboangiitis obliterans: 10-year results. |
| Q57166884 | Autologous cells derived from different sources and administered using different regimens for 'no-option' critical lower limb ischaemia patients |
| Q42593149 | Autologous stromal vascular fraction therapy for rheumatoid arthritis: rationale and clinical safety |
| Q34620003 | Bilateral administration of autologous CD133+ cells in ambulatory patients with refractory critical limb ischemia: lessons learned from a pilot randomized, double-blind, placebo-controlled trial |
| Q38432111 | Biodistribution of locally or systemically transplantedosteoblast-like cells. |
| Q38132964 | Cell transplantation as a pain therapy targets both analgesia and neural repair |
| Q36014060 | Cellular therapy with Ixmyelocel-T to treat critical limb ischemia: the randomized, double-blind, placebo-controlled RESTORE-CLI trial. |
| Q40244927 | Characterization of the Cellular Output of a Point-of-Care Device and the Implications for Addressing Critical Limb Ischemia |
| Q26998587 | Concise review: therapeutic potential of adipose tissue-derived angiogenic cells |
| Q30458139 | Critical limb ischemia: current approach and future directions |
| Q38936941 | Development of a surrogate potency assay to determine the angiogenic activity of Stempeucel®, a pooled, ex-vivo expanded, allogeneic human bone marrow mesenchymal stromal cell product |
| Q61846354 | Engineering Integrative Stem Cell and Biomaterial Therapies for Peripheral Artery Disease |
| Q38380661 | Evaluation of Cell Therapy on Exercise Performance and Limb Perfusion in Peripheral Artery Disease: The CCTRN PACE Trial (Patients With Intermittent Claudication Injected With ALDH Bright Cells). |
| Q36923569 | From bench to bedside: review of gene and cell-based therapies and the slow advancement into phase 3 clinical trials, with a focus on Aastrom's Ixmyelocel-T. |
| Q42181707 | Gene therapy and cell-based therapies for therapeutic angiogenesis in peripheral artery disease |
| Q34503028 | Guanylate-binding protein 1 expression from embryonal endothelial progenitor cells reduces blood vessel density and cellular apoptosis in an axially vascularised tissue-engineered construct |
| Q38266756 | Imaging techniques to evaluate cell therapy in peripheral artery disease: state of the art and clinical trials. |
| Q39234655 | Intra-arterial allogeneic mesenchymal stem cells for critical limb ischemia are safe and efficacious: report of a phase I study |
| Q36861575 | Optimized processing of growth factor mobilized peripheral blood CD34+ products by counterflow centrifugal elutriation |
| Q30590258 | Primary progressive multiple sclerosis: progress and challenges. |
| Q50067239 | Rationale and design of the Clinical and Histologic Analysis of Mesenchymal Stromal Cells in AmPutations (CHAMP) trial investigating the therapeutic mechanism of mesenchymal stromal cells in the treatment of critical limb ischemia |
| Q57176528 | Role of White Blood Cells in Blood- and Bone Marrow-Based Autologous Therapies |
| Q38001506 | Safety and efficacy of autologous cell therapy in critical limb ischemia: a systematic review |
| Q41090665 | Safety and efficacy of sustained release of basic fibroblast growth factor using gelatin hydrogel in patients with critical limb ischemia. |
| Q26824484 | Stem cell therapy for lower extremity diabetic ulcers: where do we stand? |
| Q91905974 | The burden of critical limb ischemia: a review of recent literature |
| Q38591798 | The role of adult tissue-derived stem cells in chronic leg ulcers: a systematic review focused on tissue regeneration medicine. |
| Q37663453 | Therapeutic strategies for cell-based neovascularization in critical limb ischemia |
| Q36626349 | Transcatheter Arterial Infusion of Autologous CD133(+) Cells for Diabetic Peripheral Artery Disease |
| Q37697685 | VEGF treatment promotes bone marrow-derived CXCR4+ mesenchymal stromal stem cell differentiation into vessel endothelial cells |
| Q38326653 | Vascular injury and repair: a potential target for cell therapies |
Search more.